TP10 complement inhibitor: TCEL began a Phase I/II trial

T Cell Sciences Inc. (TCEL), Needham, Mass. Product: TP10 complement inhibitor Indication: Reperfusion injury in lung transplants Status: TCEL began a Phase I/II trial in 60 patients with end-stage pu...